newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes Clinical